CN116057045A - 成纤维细胞生长因子受体激酶抑制剂 - Google Patents

成纤维细胞生长因子受体激酶抑制剂 Download PDF

Info

Publication number
CN116057045A
CN116057045A CN202180057232.9A CN202180057232A CN116057045A CN 116057045 A CN116057045 A CN 116057045A CN 202180057232 A CN202180057232 A CN 202180057232A CN 116057045 A CN116057045 A CN 116057045A
Authority
CN
China
Prior art keywords
optionally substituted
mmol
pharmaceutically acceptable
solvate
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180057232.9A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂芬·W·卡尔多
约翰·泰霍纳斯
埃里克·A·墨菲
陶菲克·卡努尼
李·D·阿诺德
罗伯特·卡尼亚
詹森·M·考克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinnaite Biopharmaceutical Co
Original Assignee
Jinnaite Biopharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinnaite Biopharmaceutical Co filed Critical Jinnaite Biopharmaceutical Co
Publication of CN116057045A publication Critical patent/CN116057045A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180057232.9A 2020-06-05 2021-06-04 成纤维细胞生长因子受体激酶抑制剂 Pending CN116057045A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063035155P 2020-06-05 2020-06-05
US63/035,155 2020-06-05
US202063106812P 2020-10-28 2020-10-28
US63/106,812 2020-10-28
PCT/US2021/035854 WO2021247969A1 (en) 2020-06-05 2021-06-04 Inhibitors of fibroblast growth factor receptor kinases

Publications (1)

Publication Number Publication Date
CN116057045A true CN116057045A (zh) 2023-05-02

Family

ID=78829924

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180057232.9A Pending CN116057045A (zh) 2020-06-05 2021-06-04 成纤维细胞生长因子受体激酶抑制剂

Country Status (15)

Country Link
US (3) US11345681B1 (https=)
EP (1) EP4161656A4 (https=)
JP (1) JP2023529867A (https=)
KR (1) KR20230035031A (https=)
CN (1) CN116057045A (https=)
AU (1) AU2021282596A1 (https=)
BR (1) BR112022024729A2 (https=)
CA (1) CA3181162A1 (https=)
CL (1) CL2022003427A1 (https=)
CO (1) CO2022018806A2 (https=)
IL (1) IL298760A (https=)
MX (1) MX2022015410A (https=)
SA (1) SA522441624B1 (https=)
TW (1) TW202210472A (https=)
WO (1) WO2021247969A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115867547A (zh) * 2020-08-27 2023-03-28 上海和誉生物医药科技有限公司 一种1h-吡唑-4-酰胺衍生物，其制备方法和应用
CN116685582A (zh) * 2021-01-12 2023-09-01 北京诺诚健华医药科技有限公司 (s)-1-(1-丙烯酰吡咯烷-3-基)-3-((3,5-二甲氧苯基)乙炔基)-5-(甲基氨基)-1h-吡唑-4-甲酰胺的制备工艺

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11345681B1 (en) 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
KR20240119095A (ko) * 2021-12-08 2024-08-06 킨네이트 바이오파마 인크. Fgfr 저해제의 고체 상태 형태
WO2023107870A1 (en) * 2021-12-08 2023-06-15 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
AU2022407439A1 (en) * 2021-12-08 2024-06-27 Kinnate Biopharma Inc. Treatment of cancer with an fgfr kinase inhibitor
CN115232074A (zh) * 2022-08-22 2022-10-25 湖南复瑞生物医药技术有限责任公司 一种1-烷基取代-2-甲基-5-溴苯并咪唑的合成方法
WO2024167423A1 (en) 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds
WO2025257786A1 (en) * 2024-06-13 2025-12-18 Iama Therapeutics S.R.L. Benzoimidazole derivatives as nkcc1 inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130190496A1 (en) * 2004-04-02 2013-07-25 OSI Pharmaceuticals, LLC 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors
CN104341425A (zh) * 2013-08-08 2015-02-11 上海医药集团股份有限公司 氘代乙炔衍生物、其药物组合物及应用
AU2014291161A1 (en) * 2013-07-18 2016-02-25 Taiho Pharmaceutical Co., Ltd. Antitumor drug for intermittent administration of FGFR inhibitor
US20190210997A1 (en) * 2016-09-19 2019-07-11 Beijing Innocare Pharma Tech Co., Ltd. Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof
CN110139865A (zh) * 2016-12-29 2019-08-16 石药集团中奇制药技术（石家庄）有限公司 Fgfr抑制剂
WO2020236524A1 (en) * 2019-05-17 2020-11-26 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US5886022A (en) 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
SI9600371B (sl) 1996-12-18 2005-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Etilidenski derivati tricikličnih karbapenemov
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
ES2289161T3 (es) 2001-11-02 2008-02-01 Glaxo Group Limited Derivados de 4-(heteroaril de 6 miembros)-acil pirrolidina como inhibidores de hcv.
WO2003037894A1 (en) 2001-11-02 2003-05-08 Glaxo Group Limited 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
DK1519939T5 (da) 2002-07-05 2011-01-24 Targacept Inc N-Aryl-diazaspirocykliske forbindelser og fremgangsmåder til fremstilling og anvendelse deraf
JP2007527389A (ja) 2003-06-30 2007-09-27 メルク　エンド　カムパニー　インコーポレーテッド 放射性カンナビノイド−１受容体修飾因子
FR2860431A1 (fr) 2003-10-02 2005-04-08 Oreal Composition capillaire ou de mascara contenant un compose azoique, son utilisation pour stimuler ou induire la pousse des cheveux ou des cils et/ou freiner leur chute
NZ590160A (en) 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
WO2005087765A1 (en) 2004-03-04 2005-09-22 Arena Pharmaceuticals, Inc. Ligands of follicle stimulating hormone receptor and methods of use thereof
AU2005231440B9 (en) 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
JP2008510711A (ja) 2004-08-20 2008-04-10 ターガセプト，インコーポレイテッド 嗜癖治療におけるｎ−アリールジアザスピラ環状化合物の使用
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
WO2006071958A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7732607B2 (en) 2005-08-22 2010-06-08 Anatoly Mazurov Heteroaryl-substituted diazatricycloalkanes and methods of use thereof
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007064931A2 (en) 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
EP2474546A1 (en) 2006-01-23 2012-07-11 Vertex Pharmaceuticals Inc. Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007120760A2 (en) 2006-04-13 2007-10-25 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
WO2007139816A2 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007139795A1 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
PL2044056T3 (pl) 2006-07-14 2013-01-31 Novartis Ag Pochodne pirymidyny jako inhibitory ALK-5
WO2008012010A1 (en) 2006-07-27 2008-01-31 Ucb Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
ES2548353T3 (es) 2006-12-28 2015-10-15 Abbvie Inc. Inhibidores de poli(ADP-ribosa)polimerasa
EP2036906A1 (de) 2007-09-05 2009-03-18 Bayer Schering Pharma Aktiengesellschaft Azaindole als Inhibitoren der löslichen Adenylatzyklase
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
WO2009092764A1 (en) 2008-01-24 2009-07-30 Ucb Pharma, S.A. Compounds comprising a cyclobutoxy group
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
WO2010135014A1 (en) 2009-02-27 2010-11-25 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
HRP20151258T1 (hr) 2009-08-07 2016-02-26 Chugai Seiyaku Kabushiki Kaisha Derivat aminopirazola
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
AU2011232348A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
EP2550268A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011117381A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
WO2011117382A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
MX342164B (es) 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
US8735386B2 (en) 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
EP2678050B1 (en) 2011-02-24 2020-10-14 Emory University Noggin blocking compositions for ossification and methods related thereto
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
WO2012154608A1 (en) 2011-05-06 2012-11-15 Intellikine, Llc Reactive mtor and pi3 kinase inhibitors and uses thereof
WO2013025484A1 (en) 2011-08-12 2013-02-21 Lapchak Paul A Polyphenol analogs to treat ischemia
JP2014524426A (ja) 2011-08-12 2014-09-22 ソーク インスティテュート フォー バイオロジカル スタディーズ 神経保護ポリフェノールアナログ
BR112014009037A2 (pt) 2011-10-18 2017-05-09 Syngenta Participations Ag derivados pirazol microbicidas
GB201119799D0 (en) 2011-11-16 2011-12-28 Sentinel Oncology Ltd Pharmaceutical compounds
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
EP2615083A1 (en) 2012-01-10 2013-07-17 Studiengesellschaft Kohle mbH Process for the asymmetric oxidation of organic compounds with peroxides in the presence of a chiral acid catalyst
MY171055A (en) 2012-01-19 2019-09-23 Taiho Pharmaceutical Co Ltd 3,5-disubstituted alkynylbenzene compound and salt thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
HK1205114A1 (en) 2012-04-12 2015-12-11 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
AR091023A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
CN104684906B (zh) 2012-05-11 2017-06-09 艾伯维公司 Nampt抑制剂
MX2014013758A (es) 2012-05-11 2015-02-05 Abbvie Inc Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
US9593115B2 (en) 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
WO2014158943A1 (en) 2013-03-13 2014-10-02 Avon Products, Inc Tyrosinase inhibitors
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2014145493A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Radioactive substrates for aldehyde dehydrogenase
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
AU2014268565B2 (en) 2013-05-22 2018-01-18 Curza Global, Llc Compositions and methods comprising a polyamine
AU2014283378B2 (en) 2013-06-18 2018-09-27 4Sc Ag 2,3-dihydrobenzofuran-5-yl compounds as DYRK kinase inhibitors
EA029412B1 (ru) 2013-06-28 2018-03-30 Бейджин, Лтд. Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf
WO2014210456A1 (en) 2013-06-28 2014-12-31 Emory University Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses
US10124003B2 (en) 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
WO2015011284A2 (en) 2013-07-25 2015-01-29 Fondazione Telethon Inhibitors of fapp2 and uses thereof
JP6800750B2 (ja) 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
CA2922341C (en) 2013-08-28 2022-06-07 Vanderbilt University Substituted indole mcl-1 inhibitors
WO2015039613A1 (zh) 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
KR101879422B1 (ko) 2013-09-18 2018-07-17 베이징 한미 파마슈티컬 컴퍼니 리미티드 Btk 및/또는 jak3 키나제의 활성을 억제하는 화합물
WO2015073833A1 (en) 2013-11-15 2015-05-21 Pharmacyclics, Inc. Methods for delaying or preventing the onset of type 1 diabetes
CN105979948A (zh) 2013-12-05 2016-09-28 安塞塔制药公司 Pi3k抑制剂和btk抑制剂的治疗组合
WO2015134357A1 (en) 2014-03-03 2015-09-11 Emory University Modulators of insulin receptor
WO2016010926A1 (en) 2014-07-14 2016-01-21 Pharmacyclics Llc Btk inhibitors for the treatment of cns malignancies
HRP20210927T1 (hr) 2014-08-15 2021-09-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Spojevi pirolopirimidina koje se koriste kao agonist tlr7
WO2016040449A1 (en) 2014-09-10 2016-03-17 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
JP6820254B2 (ja) 2014-10-10 2021-01-27 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用
EP3242874B1 (en) 2015-01-09 2018-10-31 Genentech, Inc. Pyridazinone derivatives and their use in the treatment of cancer
PT3279202T (pt) 2015-03-31 2020-08-31 Taiho Pharmaceutical Co Ltd Cristal de composto de alquinilo de benzeno 3,5-dissubstituído
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US11476426B2 (en) 2016-02-03 2022-10-18 Sfc Co., Ltd. Organic light emitting compounds and organic light emitting devices including the same
CN107513068A (zh) * 2016-06-16 2017-12-26 中国科学院上海药物研究所 一种具有fgfr抑制活性的新型化合物及其制备和应用
CN107698593A (zh) 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
US10882856B2 (en) 2016-09-24 2021-01-05 Beigene, Ltd. 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573966A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused n-heterocyclic compounds and methods of use thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
TW201902875A (zh) 2017-03-15 2019-01-16 美商亞瑟尼克斯公司 聯芳基哌啶醯胺化合物及其使用方法
CN108623562A (zh) 2017-03-24 2018-10-09 中国海洋大学 一种喹啉酮生物碱类化合物及其制备方法和应用
CN108658974A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种内酰胺类化合物及其制备方法和用途
CN108658972A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种取代内酰胺类化合物及其制备方法和用途
CN108690016B (zh) 2017-04-11 2022-08-12 广东东阳光药业有限公司 吡唑并吡啶类化合物及其用途
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
WO2019023448A1 (en) 2017-07-26 2019-01-31 Emory University INHIBITORS OF NADPH OXIDASE AND THEIR USE
WO2019034076A1 (zh) 2017-08-15 2019-02-21 南京明德新药研发股份有限公司 Fgfr抑制剂及其医药用途
EP3668861A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
CN110117285B (zh) 2018-02-07 2023-02-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
WO2019195278A1 (en) 2018-04-02 2019-10-10 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
TW202021969A (zh) 2018-05-31 2020-06-16 南韓商Ｃ＆Ｃ新藥研究所 雜環衍生物及其用途
CN112243439A (zh) 2018-06-13 2021-01-19 百济神州有限公司 作为hpk1抑制剂的吡咯并[2,3-b]吡啶或吡咯并[2,3-b]吡嗪及其用途
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
TW202106684A (zh) 2019-05-03 2021-02-16 美商奇奈特生物製藥公司 Raf激酶抑制劑
TW202128174A (zh) 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN116096707A (zh) 2020-06-05 2023-05-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶的抑制剂
US11345681B1 (en) 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
KR20240119095A (ko) 2021-12-08 2024-08-06 킨네이트 바이오파마 인크. Fgfr 저해제의 고체 상태 형태
WO2023107870A1 (en) 2021-12-08 2023-06-15 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
AU2022407439A1 (en) 2021-12-08 2024-06-27 Kinnate Biopharma Inc. Treatment of cancer with an fgfr kinase inhibitor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130190496A1 (en) * 2004-04-02 2013-07-25 OSI Pharmaceuticals, LLC 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors
AU2014291161A1 (en) * 2013-07-18 2016-02-25 Taiho Pharmaceutical Co., Ltd. Antitumor drug for intermittent administration of FGFR inhibitor
CN104341425A (zh) * 2013-08-08 2015-02-11 上海医药集团股份有限公司 氘代乙炔衍生物、其药物组合物及应用
US20190210997A1 (en) * 2016-09-19 2019-07-11 Beijing Innocare Pharma Tech Co., Ltd. Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof
CN110139865A (zh) * 2016-12-29 2019-08-16 石药集团中奇制药技术（石家庄）有限公司 Fgfr抑制剂
WO2020236524A1 (en) * 2019-05-17 2020-11-26 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115867547A (zh) * 2020-08-27 2023-03-28 上海和誉生物医药科技有限公司 一种1h-吡唑-4-酰胺衍生物，其制备方法和应用
CN115867547B (zh) * 2020-08-27 2024-12-20 上海和誉生物医药科技有限公司 一种1h-吡唑-4-酰胺衍生物，其制备方法和应用
CN116685582A (zh) * 2021-01-12 2023-09-01 北京诺诚健华医药科技有限公司 (s)-1-(1-丙烯酰吡咯烷-3-基)-3-((3,5-二甲氧苯基)乙炔基)-5-(甲基氨基)-1h-吡唑-4-甲酰胺的制备工艺

Also Published As

Publication number Publication date
BR112022024729A2 (pt) 2023-02-28
CA3181162A1 (en) 2021-12-09
KR20230035031A (ko) 2023-03-10
TW202210472A (zh) 2022-03-16
US11345681B1 (en) 2022-05-31
WO2021247969A1 (en) 2021-12-09
US12331039B2 (en) 2025-06-17
EP4161656A4 (en) 2024-06-19
SA522441624B1 (ar) 2025-04-10
EP4161656A1 (en) 2023-04-12
US20250333399A1 (en) 2025-10-30
CL2022003427A1 (es) 2023-06-30
CO2022018806A2 (es) 2022-12-30
AU2021282596A1 (en) 2023-01-19
US20230078839A1 (en) 2023-03-16
IL298760A (en) 2023-02-01
MX2022015410A (es) 2023-03-13
JP2023529867A (ja) 2023-07-12

Similar Documents

Publication Publication Date Title
CN116057045A (zh) 成纤维细胞生长因子受体激酶抑制剂
KR101548443B1 (ko) 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진
EP2718295A1 (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
CN112125901A (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
KR20160086930A (ko) 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도
WO2021247971A1 (en) Inhibitors of fibroblast growth factor receptor kinases
JP2025060928A (ja) 複素環化合物、これを含む薬物組成物、その製造方法および使用
KR20210124961A (ko) 티로신 키나제 억제제, 조성물 및 방법
WO2023150681A1 (en) Inhibitors of raf kinases
CN119013030A (zh) Cdk4/6激酶的抑制剂
AU2021294035A1 (en) Sulphonamide compounds
HK40085563A (en) Inhibitors of fibroblast growth factor receptor kinases
WO2023107870A1 (en) Inhibitors of fibroblast growth factor receptor kinases
WO2019013562A1 (ko) 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
TW202245758A (zh) 作為丙酮酸激酶活化劑之吡咯啶-吡唑
CN121889381A (zh) 作为治疗癌症的cdk抑制剂的4-((5-(3-(4-(吡啶-2-基)环戊基)-1h-吡唑-3-基)氨基)-苯磺酰胺衍生物和类似化合物
HK1193814A (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40085563

Country of ref document: HK